Nuvation Bio Inc. 8-K

What Happened
Nuvation Bio Inc. announced on June 30, 2026 that it closed a registered public offering of $250.0 million aggregate principal amount of 0.75% Convertible Senior Notes due 2032. The offering was conducted under an underwriting agreement dated June 25, 2026 with Jefferies, Citigroup and Cantor Fitzgerald as representatives. The Company also entered a First Amendment to its March 3, 2025 Revenue Interest Financing Agreement on June 24, 2026 to permit issuance of the Notes and related capped call transactions. The Notes were issued under an indenture with U.S. Bank Trust Company, N.A. as trustee.

Key Details

• Offering size and structure: $250.0M of 0.75% convertible senior notes due July 1, 2032; underwriters have a 30‑day option to buy up to an additional $37.5M.
• Conversion mechanics: initial conversion rate of 127.4941 shares per $1,000 principal (about $7.84 per share), an initial premium of ~35% to the June 25, 2026 NYSE close; conversion may settle in cash, shares, or a combination.
• Capped calls and costs: the company entered capped call transactions with certain banks (cap price initially $10.4580, ~80% premium) and expects to pay ~$14.9M for those hedges.
• Use of proceeds: estimated net proceeds ≈ $241.2M (≈ $277.6M if over-allotment exercised). Proceeds were used to pay the capped call cost and to repay in full the Company’s outstanding credit agreement (loan facility dated March 3, 2025); remaining proceeds for general corporate purposes.
• Key dates and restrictions: interest paid semiannually beginning Jan 1, 2027; notes not redeemable before July 6, 2029 (redeemable later if stock trades at ≥130% of then‑conversion price under specified conditions).

Why It Matters
This transaction provides Nuvation Bio with fresh liquidity and eliminates the prior loan facility, improving near‑term debt profile and cash runway without raising equity immediately. However, the convertible notes represent potential future dilution if converted (conversion price ≈ $7.84, with capped calls limiting but not eliminating dilution). The low coupon (0.75%) reduces near‑term cash interest expense compared with higher‑rate debt, but investors should watch the company’s stock price relative to the conversion price and the capped call cap price, because those levels affect when conversions, redemptions or repurchases could occur and the ultimate dilution or cash outflows.